Karki Rashmi, Lamichhane Samir, Basnet Buddha Bahadur, Dahal Anuja, Awal Bal Krishna, Mishra Shyam Kumar
Janamaitri Foundation Institute of Health Sciences, Tribhuvan University, Nepal.
National Public Health Laboratory, Kathmandu, Nepal.
Infect Drug Resist. 2021 Apr 30;14:1669-1677. doi: 10.2147/IDR.S309531. eCollection 2021.
Inappropriate use of broad-spectrum antibiotics contributes to the emergence of multidrug-resistant (MDR) bacteria. Finding novel antimicrobial agents and strategies based on synergistic combinations are essential to combat MDR infections. This study was designed to determine in vitro synergy of different antimicrobials against extensively drug-resistant (XDR) Gram-negative clinical isolates.
A descriptive, cross-sectional study was conducted at Human Organ Transplant Center, Nepal, for five months. Clinical isolates were checked for their drug-resistance properties including extended-spectrum beta-lactamase- (ESBL-) and metallo-beta-lactamase- (MBL-) production. The XDR isolates were further tested for antimicrobial synergy, and the results were interpreted as synergistic, additive, indifferent or antagonistic determining fractional inhibitory concentration of the antibiotics.
Out of total 1155 clinical samples, 308 showed significant growth. was the most common isolate (n=142) followed by complex, and miscellaneous bacteria. Out of the culture positive isolates, 21.4% were MDR and 10.06% were XDR. The XDR population comprised (18.42%), (9.86%), complex (7.41%) and (4.17%). Among the culture positive isolates, 4.5% and 5.8% were ESBL- and MBL-producers, respectively. Colistin, polymyxin B, and tigecycline were the antibiotics effective in majority of MDR isolates as compared to carbapenems. The combination of antibiotics - meropenem and colistin showed the highest proportion of "synergy" among all XDR whereas the combination of amikacin and colistin showed synergistic effect in XDR .
A significant proportion of isolates were MDR among which a large fraction was XDR. The combination of meropenem, amikacin and colistin with one another in pair showed beneficial activity in vitro. Such combinations can be utilized as effective therapy for XDR infections. Further studies are required to confirm these findings, and accordingly treatment protocols should be developed in the management of such infections.
广谱抗生素的不当使用促使多重耐药(MDR)菌的出现。寻找基于协同组合的新型抗菌剂和策略对于对抗MDR感染至关重要。本研究旨在确定不同抗菌药物对广泛耐药(XDR)革兰氏阴性临床分离株的体外协同作用。
在尼泊尔人体器官移植中心进行了一项为期五个月的描述性横断面研究。检查临床分离株的耐药特性,包括超广谱β-内酰胺酶(ESBL)和金属β-内酰胺酶(MBL)的产生。对XDR分离株进一步进行抗菌协同作用测试,并根据抗生素的分数抑菌浓度将结果解释为协同、相加、无作用或拮抗。
在总共1155份临床样本中,308份显示有显著生长。大肠埃希菌是最常见的分离株(n = 142),其次是肺炎克雷伯菌复合体、铜绿假单胞菌和其他细菌。在培养阳性分离株中,21.4%为MDR,10.06%为XDR。XDR群体包括大肠埃希菌(18.42%)、肺炎克雷伯菌(9.86%)、肺炎克雷伯菌复合体(7.41%)和铜绿假单胞菌(4.17%)。在培养阳性分离株中,分别有4.5%和5.8%是ESBL生产者和MBL生产者。与碳青霉烯类相比,黏菌素、多黏菌素B和替加环素是对大多数MDR分离株有效的抗生素。美罗培南和黏菌素的抗生素组合在所有XDR大肠埃希菌中显示出最高比例的“协同作用”,而阿米卡星和黏菌素的组合在XDR铜绿假单胞菌中显示出协同作用。
相当一部分分离株为MDR,其中很大一部分是XDR。美罗培南、阿米卡星和黏菌素两两组合在体外显示出有益的活性。这种组合可作为XDR感染的有效治疗方法。需要进一步研究来证实这些发现,并相应地制定此类感染管理的治疗方案。